AcetylCysteine as an adjunctive therapy in Bipolar Mania and its correlation with Serum Glutathione levels : A Randomised Open Label Trial - NI

Central Institute of Psychiatry0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

暂无简介。

•1. Inpatients satisfying the ICD 11- DCR criteria for Bipolar type I disorder ,
•current episode manic, with psychotic symptoms.
•2. YMRS score > 20.
•3. Age group of 18-50 years of either sex.
•4. Drug â?? naÃ¯ve patients or drug-free for a minimum of 2 weeks on mood
•stabilisers/antipsychotics and 6 weeks for depot antipsychotics.
•5. Patients started on second-generation antipsychotics and mood
•stabiliser.
•6. Those who give informed consent for participating in the study.

•1. Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine & caffeine.
•2. Significant medical or neurological illness including severe cardiovascular, hepatic, renal [serum Creatinine > 1.5 mg/dL], anemia [Hemoglobin < 11 mg/dL], history of severe head injury or myopathy or untreated thyroid disease.
•3. Pregnancy.
•4. BMI > 30 kg/m2.
•5. Known hypersensitivity to N-AcetylCysteine or any of its components.
•6. Any current systemic infection/inflammation.

发起方